| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1998PNAS...95.6037W |
| P356 | DOI | 10.1073/PNAS.95.11.6037 |
| P932 | PMC publication ID | 27581 |
| P698 | PubMed publication ID | 9600913 |
| P5875 | ResearchGate publication ID | 235609148 |
| P2093 | author name string | Wu H | |
| Smith H | |||
| Beuerlein G | |||
| Huse WD | |||
| Watkins JD | |||
| Lee BA | |||
| Nie Y | |||
| Hensler M | |||
| P2860 | cites work | Purification and functional characterization of integrin alpha v beta 5. An adhesion receptor for vitronectin | Q24301078 |
| Purification of a RAS-responsive adenylyl cyclase complex from Saccharomyces cerevisiae by use of an epitope addition method | Q24631695 | ||
| Rapid and efficient site-specific mutagenesis without phenotypic selection | Q27860608 | ||
| Replacing the complementarity-determining regions in a human antibody with those from a mouse | Q28303497 | ||
| Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 | ||
| Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis | Q29547178 | ||
| Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels | Q29619679 | ||
| Requirement of vascular integrin alpha v beta 3 for angiogenesis | Q29619681 | ||
| Discovery of human antibodies to cell surface antigens by capture lift screening of phage-expressed antibody libraries | Q32115733 | ||
| Antibody engineering by codon-based mutagenesis in a filamentous phage vector system. | Q33194650 | ||
| Protein evolution on rugged landscapes | Q34296709 | ||
| Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor | Q34346157 | ||
| Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin | Q35764323 | ||
| Vascularization of normal and neoplastic tissues grafted to the chick chorioallantois. Role of host and preexisting graft blood vessels | Q35878327 | ||
| Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system | Q36382524 | ||
| Engineering multiple properties of a protein by combinatorial mutagenesis | Q36528125 | ||
| Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis | Q36689786 | ||
| A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab. | Q36818734 | ||
| Determination of the relative affinities of antibody fragments expressed in Escherichia coli by enzyme-linked immunosorbent assay | Q36889196 | ||
| Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases | Q37362821 | ||
| Mechanisms of angiogenesis | Q38173605 | ||
| Directed evolution of a para-nitrobenzyl esterase for aqueous-organic solvents | Q38359408 | ||
| Unusual distributions of amino acids in complementarity-determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody-combining sites | Q41295516 | ||
| Kinetic maturation of an immune response | Q42018143 | ||
| Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen | Q43108382 | ||
| The Arg-Gly-Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61-203 of the beta subunit | Q44542390 | ||
| Basic FGF and TGF-beta differentially modulate integrin expression of human microvascular endothelial cells | Q46376070 | ||
| Antibody-antigen interactions: contact analysis and binding site topography. | Q47628744 | ||
| Application of a filamentous phage pVIII fusion protein system suitable for efficient production, screening, and mutagenesis of F(ab) antibody fragments. | Q54667440 | ||
| Angiogenesis | Q67897095 | ||
| Interaction of integrins alpha v beta 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites | Q68860374 | ||
| Canonical structures for the hypervariable regions of immunoglobulins | Q69450418 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6037-6042 | |
| P577 | publication date | 1998-05-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. | |
| P478 | volume | 95 |
| Q38661997 | A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor |
| Q33216580 | A general method for greatly improving the affinity of antibodies by using combinatorial libraries |
| Q42647126 | A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma |
| Q34386184 | A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications |
| Q27681289 | Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering |
| Q34736631 | Affinity maturation and fine functional mapping of an antibody fragment against a novel neutralizing epitope on human vascular endothelial growth factor. |
| Q34419541 | Affinity maturation of antiHER2 monoclonal antibody MIL5 using an epitope-specific synthetic phage library by computational design |
| Q33687487 | Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas |
| Q92978392 | Affinity-matured variants derived from nimotuzumab keep the original fine specificity and exhibit superior biological activity |
| Q34301659 | An efficient method for variable region assembly in the construction of scFv phage display libraries using independent strand amplification |
| Q33598141 | Angiogenesis in urological malignancy: prognostic indicator and therapeutic target |
| Q36897028 | Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis |
| Q34178886 | Antiangiogenesis -- therapeutic strategies and clinical implications for brain tumors |
| Q34288928 | Antiangiogenic agents and their promising potential in combined therapy |
| Q37820247 | Antibody engineering toward high-sensitivity high-throughput immunosensing of small molecules |
| Q35109771 | Antibody therapy of non-Hodgkin's B-cell lymphoma |
| Q33841864 | Beyond natural antibodies: the power of in vitro display technologies |
| Q40822573 | Deep Sequencing-guided Design of a High Affinity Dual Specificity Antibody to Target Two Angiogenic Factors in Neovascular Age-related Macular Degeneration |
| Q33283622 | Design of synthetic antibody libraries |
| Q35158112 | Development of a 'mouse and human cross-reactive' affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy. |
| Q39393866 | Differential regulation of monocyte cytokine release by αV and β(2) integrins that bind CD23. |
| Q30923970 | Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity |
| Q36040853 | Drugs to suppress cough |
| Q35654123 | Effective Optimization of Antibody Affinity by Phage Display Integrated with High-Throughput DNA Synthesis and Sequencing Technologies |
| Q79138723 | Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study |
| Q28201899 | Engineered antibodies |
| Q40865226 | Expression of antisense to integrin subunit beta 3 inhibits microvascular endothelial cell capillary tube formation in fibrin |
| Q41862260 | Fitness loss and library size determination in saturation mutagenesis |
| Q34452066 | General aspects of anti-angiogenesis and cancer therapy |
| Q39796268 | Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. |
| Q34501934 | Hypoxia as a target for combined modality treatments. |
| Q92619555 | ITGB3/CD61: a hub modulator and target in the tumor microenvironment |
| Q30724948 | Improving antibody affinity by mimicking somatic hypermutation in vitro |
| Q48391677 | In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model |
| Q44040170 | Inhibition of angiogenesis in vitro by alphav integrin-directed antisense oligonucleotides |
| Q34154425 | Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases |
| Q33983773 | Integrin alpha(v)beta(3)-Targeted Cancer Therapy |
| Q27648521 | Molecular basis for passive immunotherapy of Alzheimer's disease |
| Q38633596 | Monoclonal antibodies: technologies for early discovery and engineering |
| Q35060233 | Optimization of protein therapeutics by directed evolution |
| Q34689304 | Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. |
| Q34061211 | Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications |
| Q51174776 | Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). |
| Q91926130 | Roles of integrin in tumor development and the target inhibitors |
| Q33223036 | Selecting and screening recombinant antibody libraries |
| Q33726840 | Spatially addressed combinatorial protein libraries for recombinant antibody discovery and optimization |
| Q37592073 | Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models |
| Q36952077 | Synthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimers. |
| Q36105050 | Tailor-made antibody therapeutics |
| Q33912018 | Target molecules for anti-angiogenic therapy: from basic research to clinical trials |
| Q46255773 | The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human αVβ3 Integrin via Steric Hindrance |
| Q90212338 | The role of integrins in melanoma: a review |
| Q30773361 | Use of a peptide mimotope to guide the humanization of MRK-16, an anti-P-glycoprotein monoclonal antibody |
Search more.